EUTOS Resources

Name	Institution/Kontakt
Executive committee
Prof.Dr. Michele Baccarani Executive committee VITA	Universitá di Bologna, Italy Bologna E-Mail:baccarani@med.unibo.it
PD Dr. Guido Guidi Executive committee VITA	Head of Region Europe, Novartis Oncology E-Mail:guido.guidi@novartis.com
Prof.Dr. Francois Guilhot Executive committee VITA	Université de Poitiers, France Poitiers E-Mail:f.guilhot@chu-poitiers.fr
Prof.Dr. Rüdiger Hehlmenn Executive committee VITA	Ruprecht-Karls-Universität, Germany Heidelberg E-Mail:r.hehlmann@urz.uni-heidelberg.de
Prof.Dr. Andreas Hochhaus Executive committee VITA	Ruprecht-Karls-Universität, Germany Heidelberg E-Mail:andreas.hochhaus@med3.ma.uni-heidelberg.de

Executive committee:

Prof.Dr. Michele Baccarani (Bologna, Italy): Prof. Dr. Michele Baccarani (Bologna, Italy): Michele Baccarani isProfessor of Hematology at the University of Bologna, and Head of the Department of Hematology and Oncology “L. and A. Seràgnoli” at the S. Orsola-Malpighi University Hospital, Bologna, Italy. Professor Baccarani studied hematology at Modena University and served his residencies at the L. and A. Seràgnoli Institute of Hematology in Bologna. In the early 1980s, he was Professor of Cancer Chemotherapy at Chieti University. He later became Professor of Hematology at Trieste University. At Udine University, he was the Head of Hematology and Bone Marrow Transplantation. He returned to the University of Bologna in 2000 to head the Institute of Hematology and Medical Oncology. Professor Baccarani is past-President of the Italian Society of Experimental Hematology and the Italian Society of Hematology. Professor Baccarani has been chairman of GIMEMA CML (Gruppo Italiano Malattie Ematologiche dell'Adulto) Working Party for more than 10 years.
top

PD Dr. Guido Guidi (, Italy): Guido Guidi is Head of Region Europe, Novartis Oncology and a member of the Novartis Oncology Executive Committee. In this position, he is responsible marketing six key oncology products and coordinating operations in 35 countries. Dr. Guidi most recently served as Head of Region South-Europe, Novartis Oncology, overseeing operations of 6 countries and has held several positions in medical affairs and general management. Dr. Guidi joined Novartis as a Medical Director with LPB (Sandoz) in 1990. Before Dr. Guidi worked as Medical Director in GSK and Sharper. Dr. Guidi holds a M.D and a Ph.D. in Immunology and Rheumatology from the University of Milan, Italy. Dr. Guidi played a key role inestablishing the partnership between the European LeukemiaNet and Novartis, helping to identify a variety of areas for collaboration and advocating the aims of the network.
top

Prof.Dr. Francois Guilhot (Poitiers, France): Professor Guilhot is Director of the Clinical Investigation Center (CIC) 802 INSERM and Head of the Department of Oncology, Hematology and Cell Therapy at the Centre Hospitalier Universitaire (University Hospital Center, or CHU) of Poitiers, France. Professor Guilhot studied medicine at the University of Paris, obtaining a Masters of Human Biology in Hematology and a medical doctorate. He was Assistant Professor at l’Hôpital La Milétrie, Poitiers in the 1980s and later became Professor of Clinical Hematology and Head of the Bone Marrow Transplant Unit at the same hospital. Professor Guilhot was granted the first Award of the French Society of Hematology for Clinical Research in 1997, and is President of the Chronic Myelogenous Leukemia French Group. Professor Guilhot has been involved in the European Leukemia Net as a member of the work package 4 devoted to research in CML. He is also a member of the Executive Committee of European Treatment and Outcomes Study (EUTOS) for CML and in addition in charge of the therapeutic monitoring working group.
top

Prof.Dr. Rüdiger Hehlmenn (Heidelberg, Germany): Rüdiger Hehlmann is Professor of Medicine at the Mannheim Medical Faculty of the University Heidelberg. He is coordinator of the German CML Study Group. This group has conducted major randomized studies on the treatment of chronic myeloid leukemia (CML) over the past 26 years. Professor Hehlmann is past president of the German Society of Hematology and Oncology, past dean of his faculty and is currently Secretary General of the International Association of Comparative Research on Leukemia and Related Diseases. He is coordinator of the Competence Network on acute and chronic leukemias in Germany and also coordinates the Network of Excellence European LeukemiaNet to promote cooperation across Europe.
top

Prof.Dr. Andreas Hochhaus (Heidelberg, Germany): Andreas Hochhaus is Professor of internal medicine, hematology and oncology and head of the Leukemia Research Department at the Medical Faculty Mannheim of the University Heidelberg in Germany. The professorship for leukemia research was awarded in 2007 from the José-Carreras Leukemia foundation. He has been interested in treatment optimization of chronic myelogenous leukemia (CML) for more than 18 years, is Investigator or Co-Investigator in several Phase I, II, III and IV studies and involved in the management of the randomized CML Studies of the German CML Study Group. His special interests are the molecular monitoring of minimal residual disease and mechanisms of resistance in CML. Dr. Hochhaus is a member of the American Society of Hematology, the American Society of Clinical Oncology, the European Hematology Association, the International Association for Comparative Research on Leukemia and Related Disorders and the German Society for Hematology and Oncology.
top